Carta al Editor
Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab: comentario
Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: coment
Leído
3850
Vecesse ha leído el artículo
837
Total PDF
3013
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 2 | 2 | 4 |
| 2025 5 | 125 | 73 | 198 |
| 2025 4 | 108 | 29 | 137 |
| 2025 3 | 120 | 46 | 166 |
| 2025 2 | 82 | 30 | 112 |
| 2025 1 | 102 | 58 | 160 |
| 2024 12 | 75 | 27 | 102 |
| 2024 11 | 94 | 58 | 152 |
| 2024 10 | 40 | 24 | 64 |
| 2024 9 | 63 | 21 | 84 |
| 2024 8 | 90 | 34 | 124 |
| 2024 7 | 69 | 31 | 100 |
| 2024 6 | 81 | 30 | 111 |
| 2024 5 | 87 | 19 | 106 |
| 2024 4 | 87 | 25 | 112 |
| 2024 3 | 84 | 35 | 119 |
| 2024 2 | 70 | 31 | 101 |
| 2024 1 | 78 | 34 | 112 |
| 2023 12 | 50 | 24 | 74 |
| 2023 11 | 65 | 39 | 104 |
| 2023 10 | 85 | 42 | 127 |
| 2023 9 | 92 | 53 | 145 |
| 2023 8 | 75 | 23 | 98 |
| 2023 7 | 9 | 0 | 9 |
| 2023 6 | 13 | 6 | 19 |
| 2023 5 | 10 | 3 | 13 |
| 2023 4 | 6 | 0 | 6 |
| 2023 3 | 37 | 8 | 45 |
| 2023 2 | 12 | 8 | 20 |
| 2022 1 | 22 | 0 | 22 |
| 2022 12 | 41 | 2 | 43 |
| 2022 11 | 41 | 0 | 41 |
| 2022 10 | 40 | 4 | 44 |
| 2022 9 | 49 | 2 | 51 |
| 2022 8 | 41 | 0 | 41 |
| 2022 7 | 58 | 6 | 64 |
| 2022 6 | 78 | 2 | 80 |
| 2022 5 | 169 | 2 | 171 |
| 2022 4 | 334 | 2 | 336 |
| 2022 3 | 229 | 4 | 233 |
Mostrar todo
